James Paul Scopa - Net Worth and Insider Trading

James Paul Scopa Net Worth

The estimated net worth of James Paul Scopa is at least $3 Million dollars as of 2024-05-12. James Paul Scopa is the Director of DICE Therapeutics Inc and owns about 45,841 shares of DICE Therapeutics Inc (DICE) stock worth over $2 Million. James Paul Scopa is the Director of Conatus Pharmaceuticals Inc and owns about 1,192,080 shares of Conatus Pharmaceuticals Inc (CNAT) stock worth over $667,565. James Paul Scopa is also the Director of Adverum Biotechnologies Inc and owns about 10,333 shares of Adverum Biotechnologies Inc (ADVM) stock worth over $96,097. Details can be seen in James Paul Scopa's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that James Paul Scopa has not made any transactions after 2024-02-07 and currently still holds the listed stock(s).

Transaction Summary of James Paul Scopa

James Paul Scopa Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, James Paul Scopa owns 13 companies in total, including Adverum Biotechnologies Inc (ADVM) , Histogen Inc (HSTO) , and Radius Health Inc (RDUS) among others .

Click here to see the complete history of James Paul Scopa’s form 4 insider trades.

Insider Ownership Summary of James Paul Scopa

Ticker	Comapny	Transaction Date	Type of Owner
ADVM	Adverum Biotechnologies Inc	2024-02-07	director
HSTO	Histogen Inc	2013-07-24	director & 10 percent owner
RDUS	Radius Health Inc	2011-05-17	10 percent owner
		2016-03-02	10 percent owner
		2016-02-03	director
		2015-10-14	10 percent owner
		2015-07-21	10 percent owner
		2014-03-10	10 percent owner
		2013-05-30	10 percent owner
		2011-02-02	10 percent owner
		2012-01-26	other: Former 10% stockholder
		2023-03-17	director
		2021-04-26	director

James Paul Scopa Latest Holdings Summary

James Paul Scopa currently owns a total of 3 stocks. Among these stocks, James Paul Scopa owns 45,841 shares of DICE Therapeutics Inc (DICE) as of March 17, 2023, with a value of $2 Million and a weighting of 74.06%. James Paul Scopa owns 1,192,080 shares of Conatus Pharmaceuticals Inc (CNAT) as of July 30, 2013, with a value of $667,565 and a weighting of 22.68%. James Paul Scopa also owns 10,333 shares of Adverum Biotechnologies Inc (ADVM) as of February 7, 2024, with a value of $96,097 and a weighting of 3.26%.

Latest Holdings of James Paul Scopa

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
DICE	DICE Therapeutics Inc	2023-03-17	45,841	47.55	2,179,740
CNAT	Conatus Pharmaceuticals Inc	2013-07-30	1,192,080	0.56	667,565
ADVM	Adverum Biotechnologies Inc	2024-02-07	10,333	9.30	96,097

Holding Weightings of James Paul Scopa

James Paul Scopa Form 4 Trading Tracker

According to the SEC Form 4 filings, James Paul Scopa has made a total of 2 transactions in DICE Therapeutics Inc (DICE) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in DICE Therapeutics Inc is the sale of 10,000 shares on March 17, 2023, which brought James Paul Scopa around $290,500.

According to the SEC Form 4 filings, James Paul Scopa has made a total of 0 transactions in Conatus Pharmaceuticals Inc (CNAT) over the past 5 years. The most-recent trade in Conatus Pharmaceuticals Inc is the acquisition of 165,265 shares on July 30, 2013, which cost James Paul Scopa around $2 Million.

According to the SEC Form 4 filings, James Paul Scopa has made a total of 3 transactions in Adverum Biotechnologies Inc (ADVM) over the past 5 years, including 2 buys and 1 sells. The most-recent trade in Adverum Biotechnologies Inc is the acquisition of 10,000 shares on February 7, 2024, which cost James Paul Scopa around $135,000.

Insider Trading History of James Paul Scopa

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

James Paul Scopa Trading Performance

GuruFocus tracks the stock performance after each of James Paul Scopa's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by James Paul Scopa is -2.07%. GuruFocus also compares James Paul Scopa's trading performance to market benchmark return within the same time period. The performance of stocks bought by James Paul Scopa within 3 months outperforms 2 times out of 5 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how James Paul Scopa's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of James Paul Scopa

Average Return

Average return per transaction

Outperforming Transactions

1 out of 4 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-6.95
Relative Return to S&P 500(%)	-2.37

James Paul Scopa Ownership Network

Ownership Network List of James Paul Scopa

No Data

Ownership Network Relation of James Paul Scopa

James Paul Scopa Owned Company Details

What does Adverum Biotechnologies Inc do?

Who are the key executives at Adverum Biotechnologies Inc?

James Paul Scopa is the director of Adverum Biotechnologies Inc. Other key executives at Adverum Biotechnologies Inc include Chief Development Officer Setareh Seyedkazemi , Chief Financial Officer Linda M Rubinstein , and Chief Scientific Officer Brigit Riley .

Adverum Biotechnologies Inc (ADVM) Insider Trades Summary

Over the past 18 months, James Paul Scopa made 1 insider transaction in Adverum Biotechnologies Inc (ADVM) with a net purchase of 100,000. Other recent insider transactions involving Adverum Biotechnologies Inc (ADVM) include a net purchase of 130,000 shares made by Lupher, Jr. Mark L. , a net purchase of 100,000 shares made by Linda M Rubinstein , and a net sale of 41,239 shares made by Laurent Fischer .

In summary, during the past 3 months, insiders sold 0 shares of Adverum Biotechnologies Inc (ADVM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 6,810 shares of Adverum Biotechnologies Inc (ADVM) were sold and 33,000 shares were bought by its insiders, resulting in a net purchase of 26,190 shares.

Adverum Biotechnologies Inc (ADVM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Adverum Biotechnologies Inc Insider Transactions

No Available Data

What does Histogen Inc do?

Who are the key executives at Histogen Inc?

James Paul Scopa is the director & 10 percent owner of Histogen Inc. Other key executives at Histogen Inc include See Remarks Joyce Reyes , director & See Remarks Richard W Pascoe , and See Remarks Moya Daniels .

Histogen Inc (HSTO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Histogen Inc (HSTO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Histogen Inc (HSTO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Histogen Inc (HSTO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Histogen Inc Insider Transactions

No Available Data

What does Radius Health Inc do?

Who are the key executives at Radius Health Inc?

James Paul Scopa is the 10 percent owner of Radius Health Inc. Other key executives at Radius Health Inc include director & CEO and President G. Kelly Martin , Senior Vice President Elizabeth Messersmith , and Vice President & Sales Danielle Holtschlag .

Radius Health Inc (RDUS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Radius Health Inc (RDUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Radius Health Inc (RDUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Radius Health Inc (RDUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Radius Health Inc Insider Transactions

No Available Data

What does Syndax Pharmaceuticals Inc do?

Who are the key executives at Syndax Pharmaceuticals Inc?

James Paul Scopa is the 10 percent owner of Syndax Pharmaceuticals Inc. Other key executives at Syndax Pharmaceuticals Inc include director & Chief Executive Officer Briggs Morrison , Chief Financial Officer Keith A. Goldan , and President & Head of R&D Neil Gallagher .

Syndax Pharmaceuticals Inc (SNDX) Insider Trades Summary

Over the past 18 months, James Paul Scopa made no insider transaction in Syndax Pharmaceuticals Inc (SNDX). Other recent insider transactions involving Syndax Pharmaceuticals Inc (SNDX) include a net sale of 369,983 shares made by Briggs Morrison , a net sale of 50,069 shares made by Peter Ordentlich , and a net sale of 83,000 shares made by William Meury .

In summary, during the past 3 months, insiders sold 0 shares of Syndax Pharmaceuticals Inc (SNDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 548,588 shares of Syndax Pharmaceuticals Inc (SNDX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 548,588 shares.

Syndax Pharmaceuticals Inc (SNDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Syndax Pharmaceuticals Inc Insider Transactions

No Available Data

What does TriVascular Technologies Inc do?

Who are the key executives at TriVascular Technologies Inc?

James Paul Scopa is the director of TriVascular Technologies Inc. Other key executives at TriVascular Technologies Inc include 10 percent owner Krishna Kittu Kolluri , VP & Gen. Counsel and Secretary Kimberley A. Elting , and Chief Technology Officer Michael V. Chobotov .

TriVascular Technologies Inc (TRIV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of TriVascular Technologies Inc (TRIV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of TriVascular Technologies Inc (TRIV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

TriVascular Technologies Inc (TRIV)'s detailed insider trading history can be found in Insider Trading Tracker table.

TriVascular Technologies Inc Insider Transactions

No Available Data

What does Avalo Therapeutics Inc do?

Who are the key executives at Avalo Therapeutics Inc?

James Paul Scopa is the 10 percent owner of Avalo Therapeutics Inc. Other key executives at Avalo Therapeutics Inc include director & 10 percent owner Armistice Capital Master Fund Ltd. , 10 percent owner Caissa Capital Management Ltd. , and Interim CFO Christopher Ryan Sullivan .

Avalo Therapeutics Inc (AVTX) Insider Trades Summary

Over the past 18 months, James Paul Scopa made no insider transaction in Avalo Therapeutics Inc (AVTX). Other recent insider transactions involving Avalo Therapeutics Inc (AVTX) include a net purchase of 206,169 shares made by Caissa Capital Management Ltd. , a net sale of 3,233,542 shares made by Armistice Capital Master Fund Ltd. , and a net purchase of 6,083 shares made by Garry Arthur Neil .

In summary, during the past 3 months, insiders sold 0 shares of Avalo Therapeutics Inc (AVTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 15,348 shares of Avalo Therapeutics Inc (AVTX) were sold and 2,762 shares were bought by its insiders, resulting in a net sale of 12,587 shares.

Avalo Therapeutics Inc (AVTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Avalo Therapeutics Inc Insider Transactions

No Available Data

What does Chiasma Inc do?

Who are the key executives at Chiasma Inc?

James Paul Scopa is the 10 percent owner of Chiasma Inc. Other key executives at Chiasma Inc include director & Chief Executive Officer Raj Kannan , EVP & Chief Commerical Officer Anand Varadan , and President Mark J. Fitzpatrick .

Chiasma Inc (CHMA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Chiasma Inc (CHMA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Chiasma Inc (CHMA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Chiasma Inc (CHMA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Chiasma Inc Insider Transactions

No Available Data

What does Aratana Therapeutics Inc do?

Who are the key executives at Aratana Therapeutics Inc?

James Paul Scopa is the 10 percent owner of Aratana Therapeutics Inc. Other key executives at Aratana Therapeutics Inc include 10 percent owner Broadfin Healthcare Master Fund Ltd , 10 percent owner Broadfin Capital, Llc , and 10 percent owner Kevin Kotler .

Aratana Therapeutics Inc (PETX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aratana Therapeutics Inc (PETX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aratana Therapeutics Inc (PETX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aratana Therapeutics Inc (PETX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aratana Therapeutics Inc Insider Transactions

No Available Data

What does Epizyme Inc do?

Who are the key executives at Epizyme Inc?

James Paul Scopa is the 10 percent owner of Epizyme Inc. Other key executives at Epizyme Inc include Chief Scientific Officer Jeffery Kutok , Chief Operating Officer Jerald Korn , and Corporate Controller Joseph Beaulieu .

Epizyme Inc (EPZM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Epizyme Inc (EPZM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Epizyme Inc (EPZM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Epizyme Inc (EPZM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Epizyme Inc Insider Transactions

No Available Data

What does Pacira BioSciences Inc do?

Who are the key executives at Pacira BioSciences Inc?

James Paul Scopa is the 10 percent owner of Pacira BioSciences Inc. Other key executives at Pacira BioSciences Inc include Chief Clinical Officer Roy Winston , Executive Director & Accounting Lauren Bullaro Riker , and CAO and General Counsel Kristen Marie Williams .

Pacira BioSciences Inc (PCRX) Insider Trades Summary

Over the past 18 months, James Paul Scopa made no insider transaction in Pacira BioSciences Inc (PCRX). Other recent insider transactions involving Pacira BioSciences Inc (PCRX) include a net sale of 8,216 shares made by Lauren Bullaro Riker , a net sale of 124,338 shares made by Gary W Pace , and a net sale of 9,125 shares made by Kristen Marie Williams .

In summary, during the past 3 months, insiders sold 119,323 shares of Pacira BioSciences Inc (PCRX) in total and bought 0 shares, with a net sale of 119,323 shares. During the past 18 months, 209,500 shares of Pacira BioSciences Inc (PCRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 209,500 shares.

Pacira BioSciences Inc (PCRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pacira BioSciences Inc Insider Transactions

No Available Data

What does Verastem Inc do?

Who are the key executives at Verastem Inc?

James Paul Scopa is the other: Former 10% stockholder of Verastem Inc. Other key executives at Verastem Inc include Vice President of Finance Daniel Calkins , Chief Operating Officer Dan Paterson , and Chief Financial Officer Robert E. Gagnon .

Verastem Inc (VSTM) Insider Trades Summary

Over the past 18 months, James Paul Scopa made no insider transaction in Verastem Inc (VSTM). Other recent insider transactions involving Verastem Inc (VSTM) include a net sale of 2,240 shares made by Daniel Calkins , a net sale of 39,211 shares made by Robert E. Gagnon , and a net sale of 41,587 shares made by Brian M Stuglik .

In summary, during the past 3 months, insiders sold 1,735 shares of Verastem Inc (VSTM) in total and bought 0 shares, with a net sale of 1,735 shares. During the past 18 months, 108,848 shares of Verastem Inc (VSTM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 108,848 shares.

Verastem Inc (VSTM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Verastem Inc Insider Transactions

No Available Data

What does DICE Therapeutics Inc do?

Who are the key executives at DICE Therapeutics Inc?

James Paul Scopa is the director of DICE Therapeutics Inc. Other key executives at DICE Therapeutics Inc include 10 percent owner Northpond Ventures Gp, Llc , CSO John R. Jacobsen , and director & CEO Kevin Judice .

DICE Therapeutics Inc (DICE) Insider Trades Summary

Over the past 18 months, James Paul Scopa made 1 insider transaction in DICE Therapeutics Inc (DICE) with a net sale of 10,000. Other recent insider transactions involving DICE Therapeutics Inc (DICE) include a net sale of 37,509 shares made by John R. Jacobsen , a net purchase of 1,007,701 shares made by Ra Capital Healthcare Fund Lp , and a net sale of 2,492,871 shares made by Northpond Ventures Gp, Llc .

In summary, during the past 3 months, insiders sold 0 shares of DICE Therapeutics Inc (DICE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 2,666,925 shares of DICE Therapeutics Inc (DICE) were sold and 1,007,701 shares were bought by its insiders, resulting in a net sale of 1,659,224 shares.

DICE Therapeutics Inc (DICE)'s detailed insider trading history can be found in Insider Trading Tracker table.

DICE Therapeutics Inc Insider Transactions

No Available Data

What does Aligos Therapeutics Inc do?

Who are the key executives at Aligos Therapeutics Inc?

James Paul Scopa is the director of Aligos Therapeutics Inc. Other key executives at Aligos Therapeutics Inc include 10 percent owner Roche Holding Ltd , 10 percent owner Roche Finance Ltd , and Chief Medical Officer Matthew W. Mcclure .

Aligos Therapeutics Inc (ALGS) Insider Trades Summary

Over the past 18 months, James Paul Scopa made no insider transaction in Aligos Therapeutics Inc (ALGS). Other recent insider transactions involving Aligos Therapeutics Inc (ALGS) include a net purchase of 7,933,601 shares made by Carole Nuechterlein ,

In summary, during the past 3 months, insiders sold 0 shares of Aligos Therapeutics Inc (ALGS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aligos Therapeutics Inc (ALGS) were sold and 7,933,601 shares were bought by its insiders, resulting in a net purchase of 7,933,601 shares.

Aligos Therapeutics Inc (ALGS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aligos Therapeutics Inc Insider Transactions

No Available Data

James Paul Scopa Mailing Address

Above is the net worth, insider trading, and ownership report for James Paul Scopa. You might contact James Paul Scopa via mailing address: 601 Gateway Boulevard, Suite 350, South San Francisco Ca 94080.

Discussions on James Paul Scopa

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.